Li X, Ye Z, Lin S, et al. - Among patients suffering from hepatocellular carcinoma (HCC) and portal vein tumour thrombosis (PVTT), who received stereotactic body radiotherapy (SBRT), this investigation was carried out to assess treatment response as well as predictive factors for overall survival. Also, researchers sought to construct as well as validate a personalised prediction model for patient survival. Participants were 80 patients with HCC and PVTT, who were managed with SBRT between December 2015 and June 2019. Median survival duration was 11.5 months, and 3-, 6-, and 12-month survival rates were estimated to be 92.5, 74.5, and 47.5%, respectively. Based on five independent risk factors, a nomogram was constructed. Findings showed effectiveness of SBRT in HCC patients with PVTT. The identified independent prognostic factors for survival included clinical T stage, presence of cirrhosis, age, alpha-fetoprotein levels, and haemoglobin levels. The nomogram proposed in this study can be employed for survival prediction of patients with HCC and PVTT, who received SBRT.